Related Experiment Videos
Choroidal melanoma: I-125 plaque therapy
J L Bosworth1, S Packer, M Rotman
1Department of Radiology, North Shore University Hospital, Manhasset, NY 11030.
Radiology
|October 1, 1988
Summary
Iodine-125 eye plaque brachytherapy effectively treated choroidal melanoma in 58 patients, achieving an 87.9% disease control rate with manageable complications and no optic nerve atrophy.
Area of Science:
- Ophthalmology
- Radiation Oncology
- Oncology
Background:
- Choroidal melanoma is a rare intraocular malignancy.
- Effective treatment is crucial for preserving vision and preventing metastasis.
Purpose of the Study:
- To evaluate the efficacy and safety of iodine-125 (¹²⁵I) eye plaque brachytherapy for choroidal melanoma.
- To assess local disease control and treatment-related complications.
Main Methods:
- A cohort of 58 patients with choroidal melanoma was treated with ¹²⁵I eye plaque brachytherapy.
- Patients were followed for a mean of 48.7 months.
- Tumor characteristics, radiation dose, and outcomes were analyzed.
Main Results:
- Initial local disease control was achieved in 86.2% of patients, with an overall rate of 87.9% after re-treatment.
- Eight patients died of their disease.
- Complications were comparable to other methods, with no instances of optic nerve atrophy.
Conclusions:
- ¹²⁵I eye plaque brachytherapy is an effective treatment for choroidal melanoma.
- The treatment offers a high rate of local disease control with an acceptable safety profile.
- This method demonstrates a low risk of severe complications like optic nerve atrophy.